Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGAV | P06756 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.32 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.32 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20910141 | 0.85 | ITGB3 (0.43) | ITGB3ITGAVCHRNA7LGALS3ESR1 | |
| SCHEMBL19677577 | 0.78 | THRB (0.35) | ITGB3ITGAVTHRATHRBRXRA | |
| SCHEMBL19677582 | 0.76 | THRB (0.34) | ITGB3ITGAVTHRATHRBRXRA | |
| SCHEMBL20724700 | 0.74 | ITGB3 (0.37) | ITGB3ITGAVTHRATHRBRXRA | |
| SCHEMBL19677585 | 0.73 | ITGB3 (0.53) | ITGB3ITGAVCA9THRATHRB | |
| SCHEMBL19677591 | 0.71 | ITGB3 (0.71) | ITGB3ITGAVTHRATHRBRXRA | |
| SCHEMBL19677575 | 0.70 | ITGB3 (0.61) | ITGB3ITGAVTHRATHRBRXRA | |
| SCHEMBL20724701 | 0.68 | ITGB3 (0.33) | ITGB3ITGAV | |
| SCHEMBL19708683 | 0.66 | THRB (0.57) | ITGB3ITGAVTHRATHRBRXRA | |
| SCHEMBL23984251 | 0.65 | ITGB3 (0.52) | ITGB3ITGAVTHRATHRBRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348425-A1 | NON-CLEAVABLE POLYMER CONJUGATED WITH ALPHA V BETA 3 INTEGRIN THYROID ANTAGONISTS | NANOPHARMACEUTICALS, LLC | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348425-A1 | NON-CLEAVABLE POLYMER CONJUGATED WITH ALPHA V BETA 3 INTEGRIN THYROID ANTAGONISTS | THRA, CD44, ITGAV | ITGB3 4/4885ITGAV 3/4885CHRNA7 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.